Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets under pressure
Thu, 16 Oct 01:30 pm

The Indian stock markets extended losses during the previous two hours of trade led by heavy selling activity across the market segment. Among the broader market segment, BSE Smallcap is leading the losers. Sectoral stocks of consumer durables and metals are leading among the pack of losers, whereas stocks from FMCG and pharma were among the few sectors trading firm today.

The BSE-Sensex is trading down by 102 points and the NSE-Nifty is trading down by 37 points. The BSE Mid Cap index is trading down 0.6% and the BSE Small Cap index is trading down 0.8% today. The rupee is trading at 61.10 to the US dollar.

Power stocks are trading on a mixed note today. NHPC and Adani Power are leading the stock of gainers, whereas Indiabulls Power and KSK Energy are trading in the red today. As per a leading business daily, the country's largest state run power producer NTPC is expediting its plan to enter into the distribution businesses. The company has long stayed away from the power distribution business. However, it plans to bid for distribution rights in cities which are opening up for private players. Currently very few cities at present have private distributors along with joint venture with public utilities. Many states in a bid to incorporate efficiency are opening up the segment for private players or with public partnership. NTPC sees this as an opportunity of participating in the bids. The stock of NTPC is trading lower by 0.6% at the time of writing.

Domestic pharma stocks are trading mixed with Wockhardt and Indoco Remedies being among major gainers. However, Dishman Pharma and Natco Pharma are the biggest losers today. As per a leading financial daily, Ranbaxy Laboratories has agreed to pay $39.7 m for the settlement of its litigation pertaining to Texas Medicaid. Texas Medicaid is a US federal-state healthcare programme for the poor. The claims in the litigation are related to historical pricing data of drugs reported by Ranbaxy to Texas Medicaid. Ranbaxy will be making the payments in tranches through August 2015. Ranbaxy stock is currently trading up 0.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets under pressure". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.